Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice
Related Experiment Video
Updated: Jul 14, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Emmanuelle Lagrue1, Sylvie Chalon, Sylvie Bodard
1Inserm, U619, Tours, F-37000 France.
Abstract:
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) inhibits the mitochondrial complex I of the respiratory chain. This results in ATP and ion homeostasis disturbances, which lead to selective death of the substantia nigra dopaminergic neurons. Well known as a Parkinson's disease model, the MPTP animal model also provides a potential paradigm of the energy deficiencies found in childhood. In these conditions, anticonvulsants may provide neuroprotection by limiting cellular energy consumption. We tested valproate, topiramate and lamotrigine in the MPTP mouse model. Dopamine transporter (DAT) density was assessed by quantitative autoradiography, tyrosine hydroxylase (TH) was evaluated by immunohistochemistry and dopamine (DA) levels by HPLC-ED whereas neuronal apoptosis was monitored through active caspase-3. Expectedly, the DAT density, TH immunoreactive neurons and DA content in the MPTP group were respectively reduced to 51%, 40% and 26% versus control animals. Unlike valproate and topiramate, lamotrigine provided a significant neuroprotection against MPTP in maintaining these levels at 99%, 74% and 58% respectively and reducing the induced apoptosis. Altogether, the data indicate that lamotrigine limits dopaminergic neuronal death in the substantia nigra and promotes striatal dendrites sprouting. Lamotrigine, a widely used and well-tolerated molecule in young patients, could represent a valuable adjuvant therapy in various energy deficiency conditions during childhood.
Insights
Lamotrigine demonstrated significant neuroprotection in a mouse model of Parkinson's disease, preserving dopamine levels and reducing neuronal death. This suggests potential therapeutic benefits for childhood energy deficiency conditions.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces Parkinsonism by inhibiting mitochondrial complex I, leading to dopaminergic neuron death.
- MPTP models energy deficiencies relevant to certain childhood conditions, where anticonvulsants might offer neuroprotection by reducing cellular energy demand.
Purpose of the Study:
- To evaluate the neuroprotective effects of anticonvulsants (valproate, topiramate, lamotrigine) in the MPTP mouse model.
- To assess the impact of these drugs on dopaminergic neuron survival and function.
Main Methods:
- MPTP mouse model of Parkinson's disease.
- Assessment of dopamine transporter (DAT) density, tyrosine hydroxylase (TH) immunoreactivity, and dopamine (DA) levels.
- Monitoring of neuronal apoptosis via active caspase-3.
Main Results:
- MPTP significantly reduced DAT density, TH neurons, and DA levels.
- Lamotrigine, but not valproate or topiramate, significantly preserved DAT density, TH neurons, and DA levels.
- Lamotrigine also reduced MPTP-induced apoptosis and promoted striatal dendrite sprouting.
Conclusions:
- Lamotrigine confers significant neuroprotection against MPTP-induced dopaminergic neurodegeneration.
- Lamotrigine's ability to limit neuronal death and promote sprouting suggests its potential as an adjuvant therapy for childhood energy deficiency disorders.
